[저자] Amit Saraf, Rohan Gurjar, Swarnendu Kaviraj, Aishwarya Kulkarni, Durgesh Kumar, Ruta Kulkarni, Rashmi Virkar, Jayashri Krishnan, Anjali Yadav, Ekta Baranwal, Ajay Singh, Arjun Raghuwanshi, Praveen Agarwal, Laxman Savergave, Sanjay Singh, the GEMCOVAC-OM Study InvestigatorsPophaleHimanshu5ShendePrakash6ShindeRavindra Baban7VikheVikram8KarmalkarAbhishek9DeshmukhBhaskar10GiriKrishna11DeshpandeShrikant12BulleAjay13SiddiquiMd. Sabah14BorthakurSwapnav15TummuruV. Reddy16RaoA. Venkateshwar17ShuklaDhaiwat18JainManish Kumar19BhardwajPankaj20SupePravin Dinkar21DasManoja Kumar22LahotiManoj23BargeVijaykumar24, Himanshu Pophale, Prakash Shende, Ravindra Baban Shinde, Vikram Vikhe, Abhishek Karmalkar, Bhaskar Deshmukh, Krishna Giri, Shrikant Deshpande, Ajay Bulle, Md. Sabah Siddiqui, Swapnav Borthakur, V. Reddy Tummuru, A. Venkateshwar Rao, Dhaiwat Shukla, Manish Kumar Jain, Pankaj Bhardwaj, Pravin Dinkar Supe, Manoja Kumar Das, Manoj Lahoti, Vijaykumar Barge
[Category] update2024,
[Article Type] Article
[Source] PMC
A self-amplifying mRNA vaccine shows promise in this new modality by eliciting neutralizing antibodies against the SARS-CoV-2 Omicron (BA.1) variant in a phase 2/3 trial.
All Keywords
【저자키워드】 Randomized controlled trials, RNA vaccines,